Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA on Friday approved icosapent ethyl (marketed as Vascepa) to lower risk for cardiovascular events in adults with triglyceride levels of 150 mg/dL or higher plus either established CV disease, or diabetes and two additional CV risk factors. Icosapent ethyl is indicated as adjunctive therapy to maximally tolerated statin treatment in such patients.
The approval was based on findings from the REDUCE-IT trial, in which icosapent ethyl was associated with a 25% reduction in CV events relative to placebo in high-risk, statin-treated patients.
Icosapent ethyl was first approved in 2012 to help lower triglycerides in adults with levels at or above 500 mg/dL.
Comment
LINK(S):
FDA news release (Free)
Updated Vascepa label (Free PDF)
Background: Physician's First Watch coverage of FDA advisory panel's November 2019 vote on expanding icosapent ethyl's label (Free)